
Tetsuya Kawamura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6403765/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney International, 2009, 76, 534-545.	5.2	1,028
2	The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney International, 2009, 76, 546-556.	5.2	892
3	Effects of antihypertensive drugs on glomerular morphology. Kidney International, 1989, 36, 626-635.	5.2	213
4	The Potential of Bone Marrow-Derived Cells to Differentiate to Glomerular Mesangial Cells. Journal of the American Society of Nephrology: JASN, 2001, 12, 1401-1409.	6.1	192
5	A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrology Dialysis Transplantation, 2014, 29, 1546-1553.	0.7	149
6	Low Glomerular Density with Glomerulomegaly in Obesity-Related Glomerulopathy. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 735-741.	4.5	97
7	A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. Journal of Nephrology, 2013, 26, 350-357.	2.0	88
8	Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clinical and Experimental Nephrology, 2009, 13, 460-466.	1.6	68
9	Association Between Tonsillectomy and Outcomes in Patients With Immunoglobulin A Nephropathy. JAMA Network Open, 2019, 2, e194772.	5.9	59
10	Measurement of serum IgA and C3 may predict the diagnosis of patients with IgA nephropathy prior to renal biopsy. Journal of Clinical Laboratory Analysis, 2000, 14, 220-223.	2.1	51
11	Nationwide survey on current treatments for IgA nephropathy in Japan. Clinical and Experimental Nephrology, 2013, 17, 827-833.	1.6	48
12	The predictive value of attenuated proteinuria at 1Âyear after steroid therapy for renal survival in patients with IgA nephropathy. Clinical and Experimental Nephrology, 2013, 17, 555-562.	1.6	24
13	Anaemia is an essential complication of ANCA-associated renal vasculitis: a single center cohort study. BMC Nephrology, 2017, 18, 337.	1.8	21
14	Reproducibility for pathological prognostic parameters of the Oxford classification of IgA nephropathy: a Japanese cohort study of the Ministry of Health, Labor and Welfare. Clinical and Experimental Nephrology, 2017, 21, 92-96.	1.6	20
15	Serum cystatin C may predict the prognostic stages of patients with IgA nephropathy prior to renal biopsy. Journal of Clinical Laboratory Analysis, 2001, 15, 25-29.	2.1	18
16	A grading system that predicts the risk of dialysis induction in IgA nephropathy patients based on the combination of the clinical and histological severity. Clinical and Experimental Nephrology, 2019, 23, 16-25.	1.6	18
17	Tonsillectomy reduces recurrence of IgA nephropathy in mesangial hypercellularity type categorized by the Oxford classification. Clinical and Experimental Nephrology, 2016, 20, 425-432.	1.6	17
18	A Predictive Clinical Grading System for Immunoglobulin A Nephropathy by Combining Proteinuria and Estimated Glomerular Filtration Rate. Nephron Clinical Practice, 2011, 118, c292-c300.	2.3	15

Tetsuya Kawamura

#	Article	IF	CITATIONS
19	Pathological sub-analysis of a multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy versus steroid pulse monotherapy in patients with immunoglobulin A nephropathy. Clinical and Experimental Nephrology, 2016, 20, 244-252.	1.6	12
20	Inflamed Glomeruli—Specific Gene Activation that Uses Recombinant Adenovirus with the Cre/loxP System. Journal of the American Society of Nephrology: JASN, 2001, 12, 2330-2337.	6.1	12
21	Primary membranoproliferative glomerulonephritis on the decline: decreased rate from the 1970s to the 2000s in Japan. Clinical and Experimental Nephrology, 2013, 17, 248-254.	1.6	11
22	Reduction of proteinuria by therapeutic intervention improves the renal outcome of elderly patients with IgA nephropathy. Clinical and Experimental Nephrology, 2016, 20, 910-917.	1.6	10
23	Treatment of IgA Nephropathy: Corticosteroids, Tonsillectomy, and Mycophenolate Mofetil. , 2007, 157, 37-43.		9
24	Rhabdomyolysis Associated with Bacteremia due to Streptococcus viridans Internal Medicine, 1995, 34, 785-789.	0.7	6
25	Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study. Clinical and Experimental Nephrology, 2015, 19, 925-932.	1.6	6
26	Transcription factor 21 expression in injured podocytes of glomerular diseases. Scientific Reports, 2020, 10, 11516.	3.3	6
27	The role of a low glomerular density and being overweight in the etiology of proteinuria in CKD patients without known glomerular diseases. Clinical and Experimental Nephrology, 2014, 18, 911-917.	1.6	4
28	Ambulatory blood pressure and tubulointerstitial injury in patients with IgA nephropathy. CKJ: Clinical Kidney Journal, 2015, 8, 716-721.	2.9	4
29	The precise long-term outcomes of adult IgA nephropathy by mail questionnaires: Better renal survival compared to earlier cohort studies. PLoS ONE, 2020, 15, e0233186.	2.5	4
30	Literature review of allograft adenovirus nephritis and a case presenting as mass lesions in a transplanted kidney without symptoms of urinary tract infection or acute kidney injury. Transplant Infectious Disease, 2021, 23, e13468.	1.7	4
31	Impact of the number of steroid pulses in tonsillectomy combined with steroid pulse therapy: a nationwide retrospective study in Japan. Clinical and Experimental Nephrology, 2021, 25, 19-27.	1.6	4
32	Polymorphism of renin-angiotensin system genes in progressive IgA nephropathy. Nephrology, 1997, 3, s719-s723.	1.6	3
33	Anti-PM/Scl Antibody-positive Systemic Sclerosis Complicated by Multiple Organ Involvement. Internal Medicine, 2021, 60, 1101-1107.	0.7	3
34	Two autosomal dominant polycystic kidney (ADPKD) cases with advanced renal dysfunction, effectively treated with tolvaptan. CEN Case Reports, 2016, 5, 87-90.	0.9	2
35	Clinicopathological characteristics of patients with immunoglobulin A nephropathy showing acute exacerbations after favorable long-term clinical courses. Clinical and Experimental Nephrology, 2016, 20, 226-234.	1.6	2
36	Reproducibility for pathological prognostic parameters of the Oxford classification of IgA nephropathy: the authors reply. Clinical and Experimental Nephrology, 2017, 21, 1137-1138.	1.6	2

Tetsuya Kawamura

#	Article	IF	CITATIONS
37	Maintenance treatment using the purine-synthesis inhibitor mizoribine in a patient with relapsing thrombotic thrombocytopenic purpura. CEN Case Reports, 2018, 7, 24-28.	0.9	2
38	Measurement of serum IgA and C3 may predict the diagnosis of patients with IgA nephropathy prior to renal biopsy. , 2000, 14, 220.		2
39	Immunohistological score of transcription factor 21 had a positive correlation with its urinary excretion and proteinuria in immunoglobulin A nephropathy. Histology and Histopathology, 2021, , 18367.	0.7	2
40	Bacterial superantigen enhances cytokine production by T-helper lymphocyte subset-2 cells and modifies glomerular lesions in experimental immunoglobulin a nephropathy. Clinical and Experimental Nephrology, 1997, 1, 83-91.	1.6	1
41	A role of BMP in the development of glomerular sclerosis. Nephrology, 2005, 10, A444-A444.	1.6	1
42	Overestimation of the risk of progression to end-stage renal disease in the poor prognosis' group according to the 2002 Japanese histological classification for immunoglobulin A nephropathy. Clinical and Experimental Nephrology, 2014, 18, 475-480.	1.6	1
43	Plasma Exchange Is Highly Effective for Antiâ€Neutrophil Cytoplasmic Antibodyâ€Associated Vasculitis Patients With Rapidly Progressive Glomerulonephritis Who Have Advanced to Dialysis Dependence: A Singleâ€Center Case Series. Therapeutic Apheresis and Dialysis, 2019, 23, 253-260.	0.9	1
44	Remission of proteinuria under therapeutic intervention and the renal outcomes in Japanese patients with lupus nephritis class III and IV. Modern Rheumatology, 2020, 30, 125-131.	1.8	1
45	Glomerular remodeling by bone marrow-derived cells after bone marrow transplantation should attenuate murine IgA nephropathy. Nephrology, 2003, 8, A95-A96.	1.6	0
46	Remodeling of renal microvasculature is strongly associated with long-term prognosis of advanced IgA nephropathy. Nephrology, 2003, 8, A120-A120.	1.6	0
47	Prognostic impact of widened peritubular capillaries associated with compensatory tubular hypertrophy in advanced IgA nephropathy. Nephrology, 2004, 9, A52-A52.	1.6	0
48	Role of lymphangiogenesis for long-term renal survival in advanced IgA nephropathy. Nephrology, 2005, 10, A438-A438.	1.6	0
49	Prospective trial of combined therapy with heparin?warfarin and renin?angiotensin system (RAS) inhibitors in progressive IgA nephropathy (IgAN). Nephrology, 2006, 11, A66-A66.	1.6	0
50	Role of obesity-related factors in development of IgA nephropathy. Nephrology, 2006, 11, A70-A70.	1.6	0
51	Tonsillectomy Monotherapy for IgA Nephropathy: A Case Series. Kidney Medicine, 2020, 2, 620-628.	2.0	0
52	Ratio of serum creatinine to cystatin C is related to leg strength in predialysis CKD patients. Clinical and Experimental Nephrology, 2021, 25, 1079-1086.	1.6	0
53	Is Tonsillectomy a Possible Treatment for IgA Nephropathy from Randomized Controlled Trial (RCT)?. , 2016, , 321-330.		0
54	VI. IgA Nephropathy. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 917-925.	0.0	0